Antipsychotics Associated with High Risk of Death in Children
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Towards a Ban on Psychiatrically Diagnosing and Drugging Children
Instead of hope and enthusiasm for their futures, too many children now grow up believing they are inherently defective, and controlled by bad genes and biochemical imbalances. They are shackled by the idea that they have ADHD and then subdued by the drugs that inevitably go along with the diagnosis. Unless something intervenes, many of them will go on to pass their days on Earth in a drug-impaired, demoralized state.
Inconvenient Truths About Antipsychotics: A Response to Goff et al
The most worrying thing about the Goff et al paper is the minimisation of the evidence that antipsychotics produce brain shrinkage. There are no studies that show progressive brain changes in people diagnosed with schizophrenia or psychosis in the absence of antipsychotic treatment.
Psychiatrists View Drug-Free Programs for Psychosis as “Unscientific,” Study Finds
A new study provides an insider’s look into how psychiatrists view the establishment of drug-free programs in Norway.
New Research Suggests Brain Abnormalities in ‘Schizophrenia’ May Result From Antipsychotics
Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.
Timberrr! Psychiatry’s Evidence Base For Antipsychotics Comes Crashing to the Ground
When I wrote Anatomy of an Epidemic, one of my foremost hopes was that it would prompt mainstream researchers to revisit the scientific literature. Was there evidence that any class of psychiatric medications—antipsychotics, antidepressants, stimulants, benzodiazepines, and so forth—provided a long-term benefit? Now epidemiologists at Columbia University and City College of New York have reported that they have done such an investigation about antipsychotics, and their bottom-line finding can be summed up in this way: Psychiatry’s “evidence base” for long-term use of these drugs does not exist.
Drug Treatment for Borderline Personality Disorder Not Supported By Evidence
New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”
Study Shows Success With Reduced Antipsychotic Use
People who reduced antipsychotic use by tapering were doing just as well after five years as those who continued using the drugs.
Study Finds Improved Functioning for ‘Schizophrenia’ Without Antipsychotics
Long-term treatment with antipsychotic drugs is currently considered the standard treatment for patients diagnosed with ‘schizophrenia.’ A new study challenges this practice, however. The...
Two-Thirds of Schizophrenia Patients Do Not Remit on Antipsychotics
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
Did You Ever Stop Taking Antipsychotics? – World Survey on Withdrawal
Antipsychotics are big business, professionals are often at a loss as to how to help people going through disturbing experiences, the voices of patients are crowded out of the equation — there are many reasons for the lack of real education and informed consent around antipsychotics. To address this gap in knowledge, we launched a world study on antipsychotic medication withdrawal.
Mental Health Professionals and Patients Often Disagree on Causes of Symptoms
A new study finds that clinicians’ disregard for mental health patients’ insight into their own condition may be detrimental to treatment.
The Recovery After an Initial Schizophrenia Episode (RAISE) Study: Notes from the Trenches
I was a psychiatrist who participated in the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE ETP). Although I welcomed the positive headlines that heralded the study's results, the reports left me with mixed feelings. What happened to render the notion that talking to people about their experiences and helping them find jobs or go back to school is something novel?
Robert Whitaker Refutes Jeffrey Lieberman; But Is Psychiatry Reformable?
When the neuroleptics-are-necessary-to-treat-schizophrenia myth falls, psychiatry is finished. And that is why the Goff et al paper was produced: a desperate attempt to maintain its position by a profession that is truly on the ropes. For psychiatry this is a death-struggle.
A Tale of Two Studies
With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?
Experts Decry Dangerous Use of Antipsychotics in Children
In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.
Do Antipsychotics Worsen Long-term Schizophrenia Outcomes? Martin Harrow Explores the Question.
Martin Harrow and Thomas Jobe have a new article coming out in Schizophrenia Bulletin that I wish would be read by everyone in our society with an interest in “mental health.” Harrow and Jobe, who conducted the best study of long-term schizophrenia outcomes that has ever been done, do not present new data in this article, but rather discuss the central question raised by their research: Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Or does it hinder it?
Gradual Tapering is Most Successful for Withdrawal from Antipsychotics
Mixed-Methods study explores the experiences of antipsychotic discontinuation among service users.
Polypharmacy/Bipolar illness
A. Bipolar Illness Before the Psychopharmacology Era
Prior to 1955, bipolar illness was a rare disorder. There were only 12,750 people hospitalized with that disorder...
Epilepsy Drugs Can Induce Psychosis in Some Patients, Study Finds
In this month’s issue of the journal Brain a new study investigates whether the drugs prescribed to control seizures can increase the risk of...
The Fat Lady Has Sung
In his latest paper, Martin Harrow focuses psychiatry's attention on a very specific question: Do antipsychotic drugs provide a long-term benefit as a treatment for psychotic symptoms? His findings are consistent with a larger body of evidence that all point to the same conclusion, which is that antipsychotics fail that efficacy test. And thus, I think it is fair to say that on this issue, the Fat Lady Has Sung, Psychiatry needs to rethink its use of these drugs.
People Diagnosed with Bipolar Disorder at Increased Risk for Parkinson’s
Increased Parkinson's risk could be related to lithium, antipsychotic, and antiepileptic drug use.
Patients With Schizophrenia Show Better Work Functioning Off Antipsychotics
20-year follow-up study finds that after four years, patients not prescribed antipsychotics have significantly better work functioning.
Will Psychiatry’s Harmful Treatment of Our Children Bring About Its Eventual Demise?
The safety of our children is a sacred obligation we strive to preserve. Anything or anyone that harms them becomes the object of our...
New Research Documents Widening Mortality Gap for Bipolar and Schizophrenia
Analysis of longitudinal data from 2000-2014 demonstrate mortality gap is widening between persons with a diagnosis of bipolar or schizophrenia compared to the general population